GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (NAS:VERU) » Definitions » EV-to-FCF

Veru (VERU) EV-to-FCF : -3.54 (As of May. 04, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Veru EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Veru's Enterprise Value is $212.23 Mil. Veru's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-59.88 Mil. Therefore, Veru's EV-to-FCF for today is -3.54.

The historical rank and industry rank for Veru's EV-to-FCF or its related term are showing as below:

VERU' s EV-to-FCF Range Over the Past 10 Years
Min: -369.16   Med: -12.18   Max: 2352.13
Current: -3.54

During the past 13 years, the highest EV-to-FCF of Veru was 2352.13. The lowest was -369.16. And the median was -12.18.

VERU's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.57 vs VERU: -3.54

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-04), Veru's stock price is $1.63. Veru's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.750. Therefore, Veru's PE Ratio for today is At Loss.


Veru EV-to-FCF Historical Data

The historical data trend for Veru's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru EV-to-FCF Chart

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.15 -90.17 -35.96 -17.89 -0.80

Veru Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.34 -0.93 -1.05 -0.80 -1.32

Competitive Comparison of Veru's EV-to-FCF

For the Biotechnology subindustry, Veru's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veru's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veru's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Veru's EV-to-FCF falls into.



Veru EV-to-FCF Calculation

Veru's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=212.231/-59.881
=-3.54

Veru's current Enterprise Value is $212.23 Mil.
Veru's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Veru  (NAS:VERU) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Veru's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.63/-0.750
=At Loss

Veru's share price for today is $1.63.
Veru's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.750.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Veru EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Veru's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Veru (VERU) Business Description

Traded in Other Exchanges
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.
Executives
Mario Eisenberger director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Lucy Lu director THE FEMALE HEALTH COMPANY, 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Harry Fisch director, 10 percent owner 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Grace Hyun director 48 NW 25TH STREET, SUITE 102, MIAMI FL 33127
Mitchell Shuster Steiner director, 10 percent owner, officer: President and CEO 175 TOYOTA PLAZA, 7TH FLOOR, MEMPHIS TN 38103
K Gary Barnette officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michele Greco officer: VP and CFO 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60654
Jesus Socorro director 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Todd Charles T Jr officer: CEO of FHC Division 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Michael L Rankowitz director 2500 LAKE COOK ROAD, RIVERWOODS IL 60015
Robert Getzenberg officer: Chief Scientific Officer 4400 BISCAYNE BOULEVARD, SUITE 888, MIAMI FL 33137
Elgar Peerschke director 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
Daniel Haines officer: CFO and COO 515 N. STATE STREET, SUITE 2225, C/O THE FEMALE HEALTH COMPANY, CHICAGO IL 60654
David R Bethune director THE FEMALE HEALTH COMPANY, 515 NORTH STATE STREET, SUITE 2225, CHICAGO IL 60610
O B Parrish director, officer: Chairman/Chief Exec. Officer

Veru (VERU) Headlines

From GuruFocus